EPA guidance on the early intervention in clinical high risk states of psychoses

European Psychiatry

Volumn 30, Issue 3, 2015, Pages 388-404

  Schmidt, S J ^a   Schultze Lutter, F ^a   Schimmelmann, B G ^a   Maric, N P ^b   Salokangas, R K R ^c   Riecher Rossler A ^d   van der Gaag, M ^e,f   Meneghelli, A ^g   Nordentoft, M ^h   Marshall, M ^i,j   Morrison, A ^i,k   Raballo, A ^l,m   Klosterkotter J ⁿ   Ruhrmann, S ⁿ  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

^k GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^l Reggio Emilia County Health System   (Italy)

^m Regione Emilia Romagna   (Italy)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Adolescents; Antipsychotics; Cognitive behavioral therapy; Early intervention in Europe; Meta analysis; Neuroprotective; Prevention; Psychosis; Risk; Youth

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; LITHIUM; OLANZAPINE; OMEGA 3 FATTY ACID; PEROSPIRONE; NEUROLEPTIC AGENT;

ANXIETY; ARTICLE; COGNITIVE THERAPY; COPING BEHAVIOR; DEPRESSION; DETERIORATION; DIET SUPPLEMENTATION; EARLY INTERVENTION; EVIDENCE BASED PRACTICE; FOLLOW UP; FUNCTIONAL STATUS; GLOBAL ASSESSMENT OF FUNCTIONING; HOPELESSNESS; HUMAN; MEDICAL SOCIETY; META ANALYSIS (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; SOCIAL ADAPTATION; SOCIAL COGNITION; STRUCTURED INTERVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ADULT; EARLY DIAGNOSIS; MALE; MOOD DISORDERS; PRACTICE GUIDELINE; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RISK FACTOR; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; HUMANS; MALE; MOOD DISORDERS; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84926226843     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.01.013     Document Type: Article

References (127)

1. Addington J., Penn D., Woods S.W., Addington D., Perkins D.O. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res 2008, 99(1-3):119-124.
2. Addington J., Epstein I., Liu L., French P., Boydell K.M., Zipursky R.B. A randomized controlled trial of cognitive-behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011, 125(1):54-61.
3. American Psychiatric Association Diagnostic and statistical manual of mental health disorders (DSM-IV) 1994, American Psychiatric Press, Washington, DC. 4th ed.
4. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67(2):146-154.
5. Bechdolf A., Wagner M., Veith V., Ruhrmann S., Pukrop R., Brockhaus-Dumke A., et al. Randomized controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry 2007, 1:71-78.
6. Bechdolf A., Müller H., Stützer H., Wagner M., Maier W., Lautenschlager M., et al. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 2011, 37(2):111-121.
7. Bechdolf A., Wagner M., Ruhrmann S., Harrigan S., Putzfeld V., Pukrop R., et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012, 200(1):22-29.
8. Berger G.E., Wood S.J., Ross M., Hamer C.A., Wellard R.M., Pell G., et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des 2012, 18(4):570-575.
9. Bertolote J.M., McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry 2005, 48(Suppl.):116-119.
10. Bodatsch M., Ruhrmann S., Wagner M., Muller R., Schultze-Lutter F., Frommann I., et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011, 69:959-966.
11. Bois C., Whalley H., McIntosh A., Lawrie S. Structural magnetic resonance imaging markers of susceptibility and transition to schizophrenia: a review of familial and clinical high risk population studies. J Psychopharmacol 2015, 29(2):144-154.
12. Bora E., Pantelis C. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophr Res 2013, 144(1-3):31-36.
13. Borenstein M. Introduction to meta-analysis 2008, 33-41. John Wiley & Sons, United Kingdom. M. Borenstein, L.V. Hedges, J.P.T. Higgins, H.R. Rothstein (Eds.).
14. Campion J., Bhui K., Bhugra D. European Psychiatric Association (EPA) guidance on prevention of mental disorders. Eur Psychiatry 2012, 27(2):68-80. European Psychiatric Association.
15. Carrion R.E., McLaughlin D., Goldberg T.E., Auther A.M., Olsen R.H., Olvet D.M., et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013, 70(11):1133-1142.
16. Cornblatt B.A., Lencz T., Smith C.W., Olsen R., Auther A.M., Nakayama E., et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007, 68(4):546-557.
17. Datta S.S., Kumar A., Wright S.D., Furtado V.A., Russell P.S. Evidence-base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull 2014, 40(2):252-254.
18. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) Behandlungsleitlinie Schizophrenie 2006, Steinkopff Verlag, Darmstadt.
19. Egerton A., Stone J.M., Chaddock C.A., Barker G.J., Bonoldi I., Howard R.M., et al. Relationship between brain glutamate levels and clinical outcome in individuals at ultra-high risk of psychosis. Neuropsychopharmacology 2014, 39(12):2891-2899.
20. European Commission Green paper -Improving the mental health of the population: towards a strategy on mental health for the European Union. Summary of consultation meetings 2005, European Commission, Brussels.
21. Fritz C.O., Morris P.E. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012, 141(1):2-18.
22. Fusar-Poli P., Deste G., Smieskova R., Barlati S., Yung A.R., Howes O., et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012, 69(6):562-571.
23. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rössler A., Schultze-Lutter F., et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70(1):107-120.
24. Fusar-Poli P., Carpenter W.T., Woods S.W., McGlashan T.H. Attenuated psychosis syndrome: ready for DSM-5.1?. Annu Rev Clin Psychol 2014, 10:155-192.
25. Fusar-Poli P., Nelson B., Valmaggia L., Yung A.R., McGuire P.K. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra-high risk. Schizophr Bull 2014, 40(1):120-131.
26. Gaebel W., Möller H.J. European guidance -a project of the European Psychiatric Association. Eur Psychiatry 2012, 27:65-67.
27. Giuliano A.J., Li H., Mesholam-Gately R.I., Sorenson S.M., Woodberry K.A., Seidman L.J. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 2012, 18(4):399-415.
28. Granö N., Kallionpää S., Karjalainen M., Edlund V., Saari E., Itkonen A., et al. Lower functioning predicts identification of psychosis risk screening status in help-seeking adolescents. Early Interv Psychiatry 2014, 10.1111/eip.12118.
29. Granö N., Karjalainen M., Anto J., Itkonen A., Edlund V., Roine M. Associations between number of different type of care meetings with social network and improvement in mental well-being in adolescents at risk of first-episode psychosis. Early Interv Psychiatry 2011, 5(3):212-218.
30. Granö N., Karjalainen M., Edlung V., Saari E., Itkonen A., Anto J., et al. Anxiety symptoms in adolescents at risk for psychosis: a comparison among help seekers. Child Adolesc Ment Health 2014, 19(2):97-101.
31. Granö N., Karjalainen M., Edlund V., Saari E., Itkonen A., Anto J., et al. Health-related quality of life among adolescents: a comparison between subjects at risk for psychosis and other help seekers. Early Interv Psychiatry 2014, 8(2):163-169.
32. Granö N., Karjalainen M., Edlund V., Saari E., Itkonen A., Anto J., et al. Changes in depression, anxiety and hopelessness symptoms during family- and community-oriented intervention for help-seeking adolescents and adolescents at risk of psychosis. Nord J Psychiatry 2014, 68(2):93-99.
33. Grant P., Gabriel F., Kuepper Y., Wielpuetz C., Hennig J. Psychosis-proneness correlates with expression levels of dopaminergic genes. Eur Psychiatry 2014, 29(5):304-306.
34. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21(10):718-779.
35. Häfner H., an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999, 249(Suppl. 4):14-26.
36. Haro J.M., Ayuso-Mateos J.L., Bitter I., Demotes-Mainard J., Leboyer M., Lewis S.W., et al. ROAMER: roadmap for mental health research in Europe. Int J Methods Psychiatr Res 2014, 23(Suppl. 1):1-14.
37. Hedge L.V., Olkin I. Statistical methods for meta-analysis 1985, Academic Press, Orlando. 1st ed.
38. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions 2011, Cochrane Collaboration.
39. Higgins J., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
40. Hooker C.I., Carol E.E., Eisenstein T.J., Yin H., Lincoln S.H., Tully L.M., et al. A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit. Schizophr Res 2014, 157(1-3):314-316.
41. Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr Neurol Psychiatr 1966, 34:409-426.
42. Hui C., Morcillo C., Russo D.A., Stochl J., Shelly G.F., Painter M., et al. Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for psychosis. Schizophr Res 2013, 148(1-3):175-180.
43. Hutton P., Taylor P.J. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 2014, 44(3):449-468.
44. Jääskeläinen E., Juola P., Hirvonen N., McGrath J.J., Saha S., Isohanni M., et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013, 39(6):1296-1306.
45. Jang J.H., Shin N.Y., Shim G., Park H.Y., Kim E., Jang G.E., et al. Longitudinal patterns of social functioning and conversion to psychosis in subjects at ultra-high risk. Aust N Z J Psychiatry 2011, 45(9):763-770.
46. Kay S.R., Fiszbein A., Opfer L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
47. Khanna P., Suo T., Komossa K., Ma H., Rummel-Kluge C., El-Sayeh H.G., et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014, 10.1002/14651858.CD006569.pub5.
48. Kim K.R., Lee S.Y., Kang J.I., Kim B.R., Choi S.H., Park J.Y., et al. Clinical efficacy of individual cognitive therapy in reducing psychiatric symptoms in people at ultra-high risk for psychosis. Early Interv Psychiatry 2011, 5(2):174-178.
49. Kirkbride J.B., Fearon P., Morgan C., Dazzan P., Morgan K., Tarrant J., et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006, 63:250-258.
50. Kline E., Thompson E., Bussell K., Pitts S., Reeves G., Schiffman J. Psychosis-like experiences and distress among adolescents using mental health services. Schizophr Res 2014, 152(2-3):498-502.
51. Klosterkötter J., Schultze-Lutter F. Prevention and early treatment. Ethics in psychiatry -European contributions 2010, 235-262. Springer Science+Business Media B.V., Heidelberg. H. Helmchen, N. Sartorius (Eds.).
52. Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Ilankovic L, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull [pii: sbu078].
53. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 2013, 4:863.
54. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
55. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94.
56. Lin A., Wood S.J., Nelson B., Brewer W.J., Spiliotacopoulos D., Bruxner A., et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 2011, 132(1):1-7.
57. Marshall M., Rathbone J. Early intervention for psychosis. Schizophr Bull 2011, 37(6):1111-1114.
58. Marshall C., Addington J., Epstein I., Liu L., Deighton S., Zipursky R. Treating young individuals at clinical high risk for psychosis. Early Interv Psychiatry 2012, 6:60-68.
59. Marvin SE, Miklowitz DJ, O'Brien MP, Cannon TD. Family-focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomized trial. Early Interv Psychiatry 2014. doi:10.1111/eip.12144.
60. Maurer K., Hörrmann F., Trendler G., Schmidt M., Haefner H. Identification of psychosis risk by the Early Recognition Inventory (ERIraos) -Description of the schedules and preliminary results on reliability and validity of the checklist. Nervenheilkunde 2006, 25(1):11-16.
61. McGlashan T.H., Johannessen J.O. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996, 22(2):201-222.
62. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T.J., Woods S.W., et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I.Study rationale and design. Schizophr Res 2003, 61:7-18.
63. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163(5):790-799.
64. McGlashan T., Walsh B., Woods S. The psychosis-risk syndrome. Handbook for diagnosis and follow-up 2010, Oxford University Press, New York, NY.
65. McGorry P.D. "A stitch in time". The scope for preventive strategies in early psychosis. Eur Arch Psychiatry Clin Neurosci 1998, 248(1):22-31.
66. McGorry P, et al. A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder. In: Australian New Zealand Clinical Trials Registry, 2010 [Internet]. [identifier: ACTRN12608000475347]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83121.
67. McGorry P.D., Killackey E.J. Early intervention in psychosis: a new evidence-based paradigm. Epidemiol Psichiatr Soc 2002, 11(4):237-247.
68. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59(10):921-928.
69. McGorry P.D., Nelson B., Phillips L.J., Yuen H.P., Francey S.M., Thampi A., et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 2013, 74(4):349-356.
70. Mental Health Services in the Capital Region Effects of neurocognitive and social-cognitive remediation in patients at ultra-high risk of psychosis (FOCUS). ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27 2014; NLM identifier: NCT02098408]. https://clinicaltrials.gov/ct2/show/NCT02098408?term=NCT02098408%26rank=1.
71. Meyer E.C., Carrión R.E., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., et al. The relationship of neurocognition and negative smyptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. Schizophr Bull 2014, 40(6):1452-1461.
72. Miklowitz D.J., O'Brien M.P., Schlosser D.A., Addington J., Candan K.A., Marshall C., et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 2014, 53(8):848-858.
73. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Cannon T., Ventura J., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003, 29(4):703-715.
74. Moher D., Liberati A., Tetzlaff J., Altman D.G. Guidance for developers of health research reporting guidelines. PLoS med 2010, 7(2):1-9. PRISMA Group.
75. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004, 185:291-297.
76. Morrison A.P., French P., Parker S., Roberts M., Stevens H., Bentall R.P., et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007, 33(3):682-687.
77. Morrison A.P., Stewart S.L., French P., Bentall R.P., Birchwood M., Byrne R., et al. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Interv Psychiatry 2011, 5(1):24-32.
78. Morrison A.P., French P., Stewart S.L., Birchwood M., Fowler D., Gumley A.I., et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012, 5(344):e2233.
79. Morrison A.P., Birchwood M., Pyle M., Flach C., Stewart S.L., Byrne R., et al. Impact of cognitive therapy on internalised stigma in people with at-risk mental states. Br J Psychiatry 2013, 203(2):140-145.
80. Mossaheb N., Schäfer M.R., Schlögelhofer M., Klier C.M., Cotton S.M., McGorry P., et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective. Schizophr Res 2013, 148:163-167.
81. Nathan Kline Institute for Psychiatric Research D-serine for the schizophrenia prodrome. ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27; NLM identifier: NCT01429454]. https://clinicaltrials.gov/ct2/show/NCT00826202?term=d-serine%26rank=5.
82. National Institute for Health and Clinical Excellence (NICE) Psychosis and schizophrenia in adults: treatment and management 2014, [Online], [accessed: 25 August 2014]. https://www.nice.org.uk/guidance/published?type=Guidelines.
83. Nelson B. Attenuated psychosis syndrome: don't jump the gun. Psychopathology 2014, 47(5):292-296.
84. Nelson B., McGorry P., Yung A., Amminger P., Francey S., Berk M., et al. The NEURAPRO (North America, Europe, Australia prodrome) study: a multicentre RCT of treatment strategies for symptomatic patients at ultra-high risk for progression to schizophrenia and related disorders. Design and study plan. Schizophr Res 2008, 102(1-3):155.
85. Nieman D.H., Ruhrmann S., Dragt S., Soen F., van Tricht M.J., Koelman J.H., et al. Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr Bull 2014, 40(6):1482-1490.
86. North Shore Long Island Jewish Health System Antidepressant and antipsychotic to treat attenuated positive and negative symptoms. ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27; NLM identifier: NCT00169988]. https://clinicaltrials.gov/ct2/show/NCT00169988?term=NCT00169988%26rank=1.
87. O'Brien M.P., Zinberg J.L., Bearden C.E., Daley M., Niendam T.A., Kopelowicz A., et al. Psycho-educational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv Psychiatry 2007, 1(4):325-332.
88. O'Brien M.P.O., Miklowitz D.J., Candan K.A., Marshall C., Domingues I., Walsh B.C., et al. A randomized trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. J Consult Clin Psychol 2014, 82(1):90-101.
89. Okuzawa N., Kline E., Fuertes J., negi S., Reeves G., Himelhoch S., et al. Psychotherapy for adoescents and young adults at high risk for psychosis: a systematic review. Early Interv Psychiatry 2014, 8(4):307-322.
90. Phillips L.J., McGorry P., Yuen H.P., Ward J., Donovan K., Kelly D., et al. Medium-term follow-up of a randomized controlled trial of interventions for young people at ultra-high risk of psychosis. Schizophr Res 2007, 96:25-33.
91. Preti A., Cella M. Randomized-controlled trials in people at ultra-high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010, 123(1):30-36.
92. Rietdijk J., Dragt S., Klaassen R., Ising H., Nieman D., Wunderink L., et al. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 2010, 11:30.
93. Ruhrmann S., Bechdolf A., Kühn K.U., Wagner M., Schultze-Lutter F., Janssen B., et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry 2007, 191(Suppl. 51):S96-S101.
94. Ruhrmann S., Paruch J., Bechdolf A., Pukrop R., Wagner M., Berning J., et al. Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatr Scand 2008, 117:357-368.
95. Ruhrmann S., Schultze-Lutter F., Klosterkötter J. Probably at-risk, but certainly ill -Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010, 120(1-3):23-37.
96. Ruhrmann S., Klosterkötter J., Bodatsch M., Bechdolf A., Schimmelmann B.G., Nikolaides A., et al. Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 2012, 18(4):550-557.
97. Rüsch N., Müller M., Heekeren K., Theodoridou A., Metzler S., Dvorsky D., et al. Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. Schizophr Res 2014, 158(1-3):82-84.
98. Rüsch N., Corrigan P.W., Heekeren K., Theodoridou A., Dvorsky D., Metzler S., et al. Well-being among persons at risk of psychosis: the role of self-labeling, shame, and stigma stress. Psychiatr Serv 2014, 65(4):483-489.
99. Salokangas R.K.R., Ruhrmann S., von Reventlow H.G., Heinimaa M., Svirskis T., From T., et al. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries 2012, 138(2-3):192-197.
100. Salokangas R.K.R., Nieman D.H., Heinimaa M., Svirskis T., Luutonen S., From T., et al. Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Soc Psychiatry Psychiatr Epidemiol 2013, 48(2):303-311.
101. Salokangas R.K.R., Heinimaa M., From T., Löyttyniemi E., Ilonen T., Luutonen S., et al. Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the EPOS project. Eur Psychiatry 2014, 29(6):371-380.
102. Schmidt S.J., Schimmelmann B.G. Evidence-based psychotherapy in children and adolescents: advances, methodological and conceptual limitations, and perspectives. Eur Child Adolesc Psychiatry 2013, 22(5):265-268.
103. Schmidt S.J., Grunert V.M., Schimmelmann B.G., Schultze-Lutter F., Michel C. Differences in coping, self-efficacy, and external control beliefs between patients at-risk for psychosis and patients with first-episode psychosis. Psychiatry Res 2014, 219(1):95-102.
104. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009, 35(1):5-8.
105. Shivashankar S., Telfer S., Arunagiriraj J., McKinnon M., Jauhar S., Krishnadas R., et al. Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25 years? Nithsdale schizophrenia survey revisited. Schizophr Res 2013, 146(1-3):349-356.
106. Smieskova R., Marmy J., Schmidt A., Bendfeldt K., Riecher-Rössler A., Walter M., et al. Do subjects at clinical high risk for psychosis differ from those with a genetic high risk? -A systematic review of structural and functional brain abnormalities. Curr Med Chem 2013, 20(3):467-481.
107. Solis M. Prevention: before the break. Nature 2014, 508(7494):12-13.
108. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013. doi:10.1136/bmj.f185.
109. Stowkowy J, Perkins DO, Woods SW, Nyman K, Addington J. Personal beliefs about experiences in those at clinical high risk for psychosis. Behav Cogn Psychother 2014. doi:10.1017/S1352465814000307.
110. Sullivan G.M., Feinn R. Using effect size -or why the P-value is not enough. J Grad Med Educ 2012, 4(3):279-282.
111. Thompson A., Papas A., Bartholomeusz C., Allott K., Amminger G.P., Nelson B., et al. Social cognition in clinical "at risk" for psychosis and first episode psychosis populations. Schizophr Res 2012, 141(2-3):204-209.
112. Tsujino N., Nemoto T., Morita K., Katagiri N., Ito S., Mizuno M. Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial. Clin Psychopharmacol Neurosci 2013, 11(3):132-136.
113. University of Calgary Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27; NLM identifier: NCT01619319]. https://clinicaltrials.gov/ct2/show/NCT01619319?term=NCT01619319%26rank=1.
114. University of California Effectiveness of neuroadaptive cognitive training in adolescents at risk for psychosis. ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27; NLM identifier: NCT00655239]. https://clinicaltrials.gov/ct2/show/NCT00655239?term=NCT00655239%26rank=1.
115. van der Gaag M., Nieman D.H., Rietdijk J., Dragt S., Ising H.K., Klaassen R.M., et al. Cognitive-behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012, 38(6):1180-1188.
116. van der Gaag M., Smit F., Bechdolf A., French P., Linszen D.H., Yung A.R., et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 months and longer-term follow-ups. Schizophr Res 2013, 149(1-3):56-62.
117. Van Tricht M.J., Ruhrmann S., Arns M., Muller R., Bodatsch M., Velthorst E., et al. Can quantitative EEG measures predict clinical outcome in subjects at clinical high risk for psychosis? A prospective multicenter study. Schizophr Res 2014, 153:42-47.
118. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382(9904):1575-1586.
119. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21(9):655-679.
120. Woods S.W., Breier A., Zipursky R.B., Perkins D.O., Addington J., Miller T.J., et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003, 54:453-464.
121. Woods S.W., Walsh B., Pearlson G.D., McGlashan T.H., Simonsen E. WC2E glycine treatment of prodromal symptoms. Schizophr Res 2006, 86(Suppl.):S7.
122. Woods S.W., Tully E.M., Walsh B.C., Hawkins K.A., Callahan J.L., Cohen S.J., et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry 2007, 191(Suppl. 51):96-101.
123. Woods S.W., Walsh B.C., Hawkins K.A., Miller T.J., Saksa J.R., D'Souza D.C., et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 2013, 23(8):931-940.
124. Yale University Randomized controlled trial of aspirin vs placebo in the treatment of pre-psychosis. ClinicalTrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [2014 August 27; NLM identifier: NCT02047539]. https://www.clinicaltrials.gov/ct2/show/NCT02047539?term=NCT02047539%26rank=1.
125. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005, 39(11-12):964-971.
126. Yung A.R., Phillips L.J., Simmons M.B., Ward J., Thompson P., French P., et al. CAARMS. Comprehensive Assessment of at Risk Mental States 2006, The PACE Clinic, ORYGEN Research Centre, University of Melbourne, Department of Psychiatry, Parkville Victoria.
127. Yung A.R., Phillips L.J., Nelson B., Francey S.M., PanYuen H., Simmons M.B., et al. Randomized controlled trial of interventions for young people at ultra-high risk for psychosis: a 6-month analysis. J Clin Psychiatry 2011, 72(4):430-440.